ArticleCureus2025
A Comparison of Outcomes for Acute Ulcerative Colitis Flares Based on the Initial Glucocorticoid Regimen Measured Against Disease Activity and Severity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory condition characterized by mucosal inflammation extending from the rectum proximally. Acute flares are traditionally managed with glucocorticoid (GC) therapy, but optimal dosing regimens remain undefined across professional societies. This study aimed to compare outcomes associated with different initial GC regimens (low, medium, high) for hospitalized patients with acute UC flares and to determine if outcomes vary based on disease activity and severity.
methodsWe conducted a retrospective chart review of hospitalized patients (age ≥18) diagnosed with UC (ICD-10 K.51) who received steroid therapy between January 2016 and November 2024. Primary outcomes included treatment escalation/improvement, changes in inflammatory markers (ESR, CRP), length of stay, colectomy rates during the index admission, and 30-day readmission. Analyses included binary logistic regression, Kruskal-Wallis tests, and negative binomial regression.
resultsAmong 2,481 patients (mean age 44.8±18.5 years, 49.1% female), the initial regimen was significantly associated with treatment trajectory. Patients starting on low regimens were 1.32 times more likely to require escalation than those on medium regimens (p=0.05). Patients starting on high regimens were 3.43 times more likely to improve compared to medium regimens (p<0.0001). Length of stay was significantly associated with the initial regimen (p=0.05), with high regimens associated with shorter stays compared to low regimens. Changes in inflammatory markers were similar across all three regimen groups. The initial regimen was not significantly associated with colectomy rates or 30-day readmissions.
conclusionThe initial GC regimen choice influences treatment trajectory and length of stay for acute UC flares, with higher initial doses associated with improved outcomes for certain metrics. These findings provide evidence to guide clinical decision-making when selecting initial GC regimens for hospitalized patients with acute UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.